VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
Rhea-AI Summary
Volition (NYSE AMERICAN: VNRX) filed a new patent application to protect use of its Nu.Q® NETs test for triaging and monitoring patients suspected of Ebola infection.
The CE-Marked automated assay and a finger-prick LFT prototype target frontline use in outbreak zones, with Volition actively seeking global strategic partners.
Positive
- Filed strategic patent application for Nu.Q® NETs Ebola triage and monitoring use
- CE-Marked automated Nu.Q® NETs assay already used in multiple clinical programs
- Finger-prick Nu.Q® NETs LFT prototype designed for bedside use in outbreak zones
- Actively inviting global partners for field trials, scale-up, and deployment
Negative
- None.
News Market Reaction – VNRX
In the Jun 3 session, VNRX declined 10.34%, reflecting a significant negative market reaction. Argus tracked a peak move of +17.0% during that session. Argus tracked a trough of -22.9% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 27 | Commercial momentum update | Positive | +0.0% | Reported Q1 2026 revenue growth and progress across multiple Nu.Q® programs. |
| May 14 | Earnings and update | Neutral | -9.1% | Detailed Q1 2026 financials, funding inflows, and development across Nu.Q® franchises. |
| May 11 | Earnings call schedule | Neutral | -8.9% | Announced timing and access details for the Q1 2026 earnings call. |
| May 6 | Nu.Q Vet manuscript | Positive | +6.9% | Submitted Nu.Q® Vet feline lymphoma manuscript tied to a potential $5M milestone. |
| Apr 29 | Sepsis LFT progress | Positive | -5.0% | Reported successful finger‑prick nucleosome detection in ICU sepsis patients via LFT prototype. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news usually sees price moves broadly aligned with sentiment, though some positive clinical/technical updates have met with selling pressure.
Over the past months, VolitionRx has highlighted growing commercial traction, with Q1 2026 revenue around $1.0 million and a 300% year-over-year increase. Updates spanned multi‑billion‑dollar TAMs in cancer detection, Nu.Q® Vet, and sepsis/NETosis, plus feasibility data for finger‑prick nucleosome detection in ICU sepsis patients. A feline lymphoma Nu.Q® Vet manuscript, tied to a potential $5 million milestone, previously drew a positive reaction. Today’s Ebola‑focused Nu.Q® NETs patent continues the pattern of expanding clinical use cases on the same technology platform.
Key Terms
nucleosomes medical
neutrophil extracellular traps medical
septic shock medical
lateral flow detection technical
filovirus medical
disseminated intravascular coagulation medical
immunosuppression medical
triage medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Seeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak Zones
Dr. Jake Micallef, Chief Scientific Officer, Volition commented:
"This filing yet again shows the breadth of utility of our technology: it claims the potential use of Volition's existing Nu.Q® NETs test for Ebola. The Nu.Q® NETs test quantifies circulating nucleosomes and Neutrophil Extracellular Traps (NETs) as early indicators of hyper-inflammation leading to septic shock and early mortality.
"Our existing patented product portfolio includes the CE-Marked automated Nu.Q® NETs assay for use in centralized laboratories, in addition to the recently announced capillary blood finger-prick lateral flow detection (LFT). The LFT could offer an unprecedented bedside triage solution for severe filovirus outbreaks, creating a compelling pathway into underserved, resource constrained countries, where laboratory infrastructure may be weak or non-existent.
"While existing Ebola diagnostics focus entirely on identifying the presence of the virus, Volition's technology focuses on the host's dysregulated immune response. The Nu.Q® NETs test measures H3.1 nucleosomes, which serve as an independent predictor of organ failure and mortality in patients with sepsis and COVID-19. Similarly, identification of elevated NETs levels prior to clinical deterioration may help field medics prevent disease spread and provide earlier, more effective treatment for Ebola-infected patients."
Meeting the Critical Need in Ebola
Ebola is a rare but severe illness in humans, with an average case fatality rate around
The ongoing Ebola outbreaks across Sub-Saharan Africa highlight a persistent medical challenge: because initial symptoms are non-specific, clinicians in remote field facilities cannot easily identify infected patients sufficiently early to prevent disease spread and for early treatment.
A Call for Strategic Partnerships
With its core laboratory automated assays already CE-Marked and in use in a number of clinical programs, Volition is looking to translate this technology into immediate field application. The company is actively inviting global health organizations, pharmaceutical developers, non-governmental organizations (NGOs), and distribution partners to collaborate on field trials, manufacturing scale-up, and potential deployment of its LFT prototypes in outbreak zones.
Mr. Remi Rabeuf, VP of Corporate Alliances and Strategic Partnerships, Volition said:
"Our Nu.Q® technology has demonstrated its potential to improve sepsis care in advanced Western settings and with this new patent filing and our successful finger-prick LFT prototype, we now hope to take this prognostic power into most low- and middle-income country healthcare settings.
"We are seeking the right institutional and commercial partners to help us get this low-cost, life-saving triage tool into the hands of frontline healthcare workers fighting Ebola."
For partnership, licensing, or media inquiries, contact our alliance team directly at mediarelations@volition.com.
- World Health Organization (Ebola Disease Factsheet).
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements or other arrangements with third parties for its products, and Volition's expectations regarding the terms of such agreements or arrangements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nu.Q®, rNuq™, Nucleosomics™, Capture-PCR™ and Capture-Seq™ and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.
View original content:https://www.prnewswire.com/news-releases/volitionrx-files-new-patent-protecting-its-nuq-nets-test-for-ebola-triage-and-treatment-monitoring-302790033.html
SOURCE VolitionRx Limited